~~<i id='ABEF46DF88'><strike id='ABEF46DF88'><tt id='ABEF46DF88'><pre id='ABEF46DF88'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

knowledge

author：hotspot 2025-10-02 07:01:35 - browse：17

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Can U.S. cancer drug shortages be fixed?

focus

hotspot

knowledge

hotspot

AdobeBiotechstartupGenerateBiomedicines,whichusesartificialintelligencetofindnewdrugs,raised$273mill

WSS

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Intellia plays down concerns on accidental germline transmission

Listen: Vivek Ramaswamy's star turn & leaky drug data

People can get long Covid without testing positive for virus: Study

Private equity could exacerbate cardiology's overuse problem, experts fear

New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

knowledge

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

People can get long Covid without testing positive for virus: Study

State Dept. review finds Biden bears some blame for Afghanistan failures

California store owner shot dead in dispute over displaying Pride flag: Police

New air purifier tech could be key to improving indoor air quality

How medical schools plan to diversify without affirmative action

Trump demands the U.S. pay no more for drugs than other countries … again

Wegovy improves function in certain heart failure patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

People can get long Covid without testing positive for virus: Study

focus

WATCH: Why do bright lights make us see spots?

Acelyrin, a rare IPO success, stumbles in its first big test

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Former Pear Therapeutics executives start new VC firm

New weight loss drugs vying to be the next Wegovy or Mounjaro

Can U.S. cancer drug shortages be fixed?

hotspot

knowledge

knowledge

hotspot